ISPC vs MET · rev $9.3M vs P/E 13, $52.16B cap
iSpecimen Inc (ISPC) versus MetLife Inc (MET) — a side-by-side from cached financials, not a winner call.
iSpecimen Inc (ISPC) is a diagnostics & research company listed on US.
MetLife Inc (MET) is a insurance - life company listed on US.
Latest reported ISPC revenue for 2024-12-31 was $9.3M. Net income was -$12.5M. Revenue was down 6.4% from 2023-12-31 to 2024-12-31. ISPC currently screens at market cap $4.4M.
MET does not have a complete income-statement cache yet.
ISPC currently screens at market cap $4.4M. MET currently screens at market cap $52.16B and trailing P/E 12.7.
Not investment advice. Open the ISPC and MET stock pages for the full models.
Not investment advice.